Objectives {#sec1-2054270415611332}
==========

Baseline neutrophil--lymphocyte ratio (NLR) has been reported to be a prognostic biomarker for survival and a predictive marker for response to treatment in prostate cancer.^[@bibr1-2054270415611332][@bibr2-2054270415611332]--[@bibr3-2054270415611332]^ It also has been hypothesised that 'in patients with a high NLR, treatment with chemotherapy might be more beneficial than Abiraterone'.^[@bibr1-2054270415611332],[@bibr3-2054270415611332]^ This hypothesis is based on retrospective analysis of data from phase III clinical trials, and hence the relevance and applicability to a 'real world' population is unknown. It is widely accepted that patients in clinical trials are physically more fit, well-motivated and have significantly less comorbidity due to restrictive trial eligibility criteria.^[@bibr4-2054270415611332],[@bibr5-2054270415611332]^ We analysed whether NLR is prognostic and predictive in an unselected group of patients.

Design {#sec2-2054270415611332}
======

Retrospective analysis of routinely collected patient data from 149 patients who were consecutively treated, with Abiraterone 1 g and Prednisolone 10 mg combination, between January 2012 and May 2014.

Setting {#sec3-2054270415611332}
=======

Nottingham University Hospital NHS Trust, Nottingham, UK.

Participants {#sec4-2054270415611332}
============

Median age was 75 years (55 to 88 years); Baseline median PSA was 52.3 ng/ml (0.03 to 6884); Median haemoglobin was 12.4 g/dL (7.6 to 16.0). Median alkaline phosphatase was 109 (38 to 2728). Bone metastasis, Nodal metastasis and Visceral metastasis were present in 90%, 38%, and 14%, respectively. Ninety-four patients (63%) were Docetaxel naive.

Main outcome measures {#sec5-2054270415611332}
=====================

The prognostic and predictive value of baseline neutrophil--lymphocyte ratio was assessed.

Results {#sec6-2054270415611332}
=======

Baseline median NLR was 3.05 (range 0.8 to 32.4) and mean NLR 4.58 (95% CI 3.82 to 5.33). The overall PSA 50% response rate was 49%. Haemoglobin \>11.0 was associated with better PSA response with an odds ratio of 2.4 (95% CI 1.2 to 4.8). Chemotherapy naive patients, as expected, also had a better response to Abiraterone with an odds ratio of 3.1 (95% CI 1.4 to 7.3).

A high NLR \>4 was confirmed to be prognostic and was associated with inferior overall survival (1-year survival rate 59% vs 77%, log rank test: *p = *0.054). But contrary to van Soest et al.^[@bibr1-2054270415611332]^ findings, NLR, as a dichotomised variable, was not predictive of treatment response at any ratio (NLR 2, 3, 4 or 5). For instance, with a NLR ratio of 4, the PSA 50% response rate was 55% versus 47% in high (\<4) and low (\<4) NLR groups, respectively (chi-square test *p*-value 0.32). Furthermore, NLR, as continuous variable, was also not predictive of treatment response (odds ratio 1.05 on logistic regression *p* 0.172).

There was no imbalance in patient characteristics such as age, baseline PSA, haemoglobin, ALP, sites of metastasis (bone, vertebral or nodes) between high (\<4) and low (\>4) NLR groups (*p*-value at least \>0.1 on Mann-Whitney, chi-square or student *t*-test as appropriate).

More patients pre-treated with Docetaxel had a high NLR of \>4 (48% vs 31.3% vs *p* = 0.046). But on subgroup analysis, NLR was not predictive of treatment response both in Docetaxel naive and Docetaxel exposed patients (Chi-square *p* 0.30 and *p* 0.784, respectively).

The discordant results could be explained by the fact that high NLR is a global and not a cancer specific biomarker.^[@bibr6-2054270415611332]^ High NLR has been associated with adverse outcomes in many common surgical and medical conditions. For instance, a high NLR is associated with increased cardiovascular disease mortality, smoking, diabetes, hypertension, hypercholesterolemia, ageing, body mass index, renal failure, metabolic syndrome, chronic obstructive pulmonary disease, and heart failure.^[@bibr6-2054270415611332]^

Conclusion {#sec7-2054270415611332}
==========

We conclude that in this non-trial population, where there is a higher prevalence of comorbid medical conditions, NLR, although prognostic, is not a useful predictive biomarker for optimising the sequencing of hormonal and chemotherapeutic agents in metastatic castration-resistant prostate cancer.
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